|
|
|
|
|
|
Elizabeth Nash Memorial
Fellowship Program
|
This fellowship program supports CF research at the post-doctoral level. One year terms may be extended to a second year of funding, based on the reviews of progress-to-date. Post-doctoral researchers and their Principal Investigators meet at semi-annual colloquia held in the Bay Area.
- Susan Lynch, Ph.D. and Weidong Kong, Ph.D. –
University of California San Francisco
"Clinical and Basic Research Studies of CF Airway Gland Secretions."
- Bruce Hammock, Ph.D. and Jun Yang Ph.D. –
University of California Davis
"A New Therapeautic Strategy Focusing on Anti-Inflammatory Therapies for Cystic
Fibrosis-Related Lung Disease: Preliminary Data Towards Consideration of Therapy
with Soluble Epoxide Hydrolase Inhibitor (sEHI)."
- Paul Quinton, Ph.D. and Ning Yang M.D., Ph.D. –
University of California San Diego
"Can Bicarbonate Help Mucus Release in Cystic Fibrosis."
- Dennis Nielson, M.D., Ph.D. and Nico Derich, M.D. –
University of California San Francisco
"Ex Vivo surrogate Assays to Assess Efficacy of Ion Channel-Targeted CF drugs."
New Horizons Research Campaign
This program supports Cystic Fibrosis research of Principal Investigators at a higher level of funding. One year terms may be extended to a second year of funding, based on the reviews, progress-to-date and availability of funds.
The following projects are currently being funded through this program:
- Terry Machen, Ph.D. –
University of California Berkeley
"Mechanism and JNK Control of Flagellin-Stimulated Inflammation and CL Secretion
by Airway Epithelia."
- Forest Rohwer, Ph.D. –
San Diego State University
"Metagenomic Analysis of Viral and Microbial Communities in Cystic Fibrosis
Lungs."
- Dieter Gruenert, Ph.D. –
University of California San Francisco
"CFTR expression levels and CFTR fuction; transgene versus endogenous."
- Daniel J. Hassett, Ph.D. –
University of Cincinnati
"Molecular Basis Underlying Killing of Mucoid Pseudomonas aeruginose by
Nitrite."
|
Moving Research Forward
As researchers answer questions on the molecular and biochemical mechanisms of CF, more questions follow as the complexity of this disease is encountered. This is why the dedication of CFRI in supporting research is so important.
CFRI’s programs—the Elizabeth Nash Memorial Fellowship and the New Horizons Campaign—have funded research such as Pseudomonas and its interaction with the epithelium, alternate signaling pathways that induce chloride channel function, the role of calcium-activated chloride channels in the lung, antioxidants and the CF lung, mucous gland regulation and secretion, and CF lung microbial populations and their role in susceptibility to infection—all critical issues for CF patients.
The grants we receive are high quality, peer reviewed, and thoughtfully evaluated by Research Advisory Committee members before final funding recommendations are made. My only regret as chair of the RAC is that we don’t have enough funds to support all the proposals we receive.
CFRI Research Advisory Committee
|
|
|
|
|
 |
|
